Novartis Pays US$75 M for Portola's Anticoagulant
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 2 (Table of Contents)
Published: 12 Feb-2009
DOI: 10.3833/pdr.v2009.i2.83 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Novartis is to pay US$75 M upfront for the worldwide rights to elinogrel, an anti-platelet drug developed by Portola Pharmaceuticals...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS